Automated delivery of high-viability therapeutic cell populations following revival from cryopreservation

该项目旨在为细胞治疗行业的客户开发一种商业示范仪器——ReVive受控解冻设备（ReVive- ct），这些客户将冷冻产品运送给患者，并需要在治疗时确保细胞的最高存活率和可重复性。结合核心生物和工程技能，以便将冷冻保存的治疗细胞的使用“制药化”——从洁净室到临床的过渡将被简化，以优化(1)向患者递送的便利性，(2)高活力和细胞剂量（因此高效率），以及(3)高质量产品的一致性和可重复性。此外，预计该系统将有额外的应用-例如在早期生物处理过程中-在这些过程中，来自储存库的细胞的控制解冻是一个重要的处理考虑因素。

The project aims to develop a commercial demonstrator instrument - the ReVive Controlled Thaw device (ReVive-CT) to customers within the cell therapy sector who ship frozen product to the patient and need to ensure the highest possible viability and reproducibility of cells at the point of treatment. Combining core biological and engineering skills in order to 'pharmaceuticalise' use of cryopreserved therapeutic cells - the transition from cleanroom to clinic will be streamlined to optimise (1) ease of delivery to the patient, (2) high-viability and cell dosage (and therefore high efficacy), and (3) consistency and reproducibility of high-quality product delivered. Furthermore, it is envisaged that the system will have additional applications - eg during early-stage bioprocessing - where controlled thawing of cells from banked stocks is an important processing consideration.